| Objective:1.To observe direct antiviral agents for Gene 1b chronic hepatitis C and compensation of HCV cirrhosis clinical outcome of effect.2.Impact of different DAAs treatment on long-term prognosis in patients with sustained virological response.Methods:138 patients with genotype 1b CHC and compensated hepatitis C cirrhosis who were treated in the outpatient department of the First Hospital of Shanxi Medical University from January 2018 to August 2019 were studied.Corresponding antiviral schemes are adopted for their own situations such as combined medication.Analyze the patients’ liver function recovery rate and virological response rate,observe the adverse drug reactions during the treatment of the patients,and observe the relevant laboratory tests during the12 weeks,24 weeks,and 48 weeks after the end of the treatment.And analyze the effect of DAAs treatment on the near-term effect and long-term prognosis of patients with chronic hepatitis C and compensatory hepatitis C cirrhosis.Results:1.Among the 138 patients,107 were CHC patients and 31 were compensated hepatitis C cirrhosis in the compensatory.Of the patients with CHC,33 were treated with Sofosbuvir and Velpatasvir(SOF+VEL),and 25 patients were treated with Elbasvir and Grazoprevir Tablets(EBR+GZR),18 patients were treated with Ombitasvir andDasabuvir(OBV+DSV),17 patients were treated with Sofosbuvir and Daclatasvir(SOF+DCV),and 14 were treated with Sofosbuvir and Ribavirin(SOF+RBV);18 patients with compensated hepatitis C cirrhosis were treated with Sofosbuvir and Velpatasvir(SOF+VEL),6 patients were treated with Elbasvir and Grazoprevir Tablets(EBR+GZR),and 7 patients were treated with Sofosbuvir and Daclatasvir(SOF+DCV)(Sofosbuvir combined with ribavirin is 24 weeks,and the rest are12 weeks).2.Of the 107 patients with CHC,49 were males and 58 were females,with an average age of(47.17 ± 13.55)years;17 of them had hypertension(5 patients took nifedipine sustained-release tablets,and 8 patients took levamlodipine besylate tablets,2patients took enalapril,2 indapamide tablets),1 patient with mild renal insufficiency,and1 patient with postpartum depression(while taking quetiapine 25mg-50 mg once daily,and Fluoxetine Hydrochloride Dispersible Tablets 20 mg,1time/d).Of the 31 patients with compensated hepatitis C cirrhosis,17 were male and 14 were female,with an average age of(59.07 ± 11.79)years.Four of these patients were complicated with hypertension(1 patient took levamlodipine besylate tablets,1 patient took enalapril,2Patients took hydrochlorothiazide tablets),and 3 patients had mild renal insufficiency.3.The overall effect is patients received 91.3% of SRVR at 1 week of DAAs,96.4% of RVR at 4 weeks of treatment,100% of cEVR at 12 weeks of treatment,SVR12 of 100% at 12 weeks after treatment,and HCV RNA remained negative after the treatment of 24 and 48 weeks.4.DAAs treatment can significantly improve the liver function of patients,and has no obvious effect on renal function and blood routine.No obvious extrahepatic manifestations and related complications occurred during the follow-up monitoring after patients obtained SVR.5.During the treatment of DAAs,the incidence of adverse events was low.Two of the 138 cases were nausea,and one case was hemolysis,rash,dizziness,and palpitations.None of the patients withdrew due to adverse reactions.Conclusion:The anti-hepatitis C treatment with DAAs has obvious curative effect,the incidence of adverse reactions is low and slighe,and the treatment course is shorter than that of interferon treatment.Different antiviral regimens can significantly improve the liver function of patients,and have no obvious effect on renal function and blood routine.No obvious extrahepatic manifestations and related complications occurred during the follow-up monitoring after patients obtained SVR.In view of the limited sample size and follow-up time of this study,the effect of DAAs treatment on patients’ long-term prognosis after SVR needs further study by clinical real-world studies. |
PDF Full Text Request